Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab extension study for participants from prior parent studies
NL-OMON60353Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of pembrolizumab and favezelimab in advanced nonhematological malignancy (2 arms), sponsored by Merck & Co. Primary endpoint: Overall Survival. Started Dec 2018; status: recruiting.
02
Drugs
pembrolizumabfavezelimab
03
Conditions
advanced nonhematological malignancy
Beyond the preview
Go deeper on NL-OMON60353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60353.